Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avricore Health (AVCRF) EPS (Weighted Average and Diluted) (2018 - 2025)

Avricore Health has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at -$0.0 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 76.35% to -$0.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.0 through Dec 2025, up 76.35% year-over-year, with the annual reading at -$0.01 for FY2025, 85.36% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.0 for Q4 2025 at Avricore Health, down from -$0.0 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.02 in Q4 2021 and troughed at -$0.02 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2024), against an average of -$0.01.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 306.85% in 2021 and then crashed 985.88% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.02 in 2021, then plummeted by 241.72% to -$0.02 in 2022, then increased by 13.37% to -$0.02 in 2023, then rose by 4.04% to -$0.02 in 2024, then skyrocketed by 76.35% to -$0.0 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's EPS (Weighted Average and Diluted) are -$0.0 (Q4 2025), -$0.0 (Q3 2025), and -$0.0 (Q2 2025).